2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML

Inclusion Criteria: * Male or female age ≥ 18 years at the time of signing the ICF * Able to understand and willing to provide written informed consent * Willing to comply with clinical study instructions and requirements. * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 (Appendix 1). * Pathologically confirmed diagnosis of AML by 2022 International Consensus Classification of Myeloid Neoplasms and Acute Leukemias criteria (2) * AML may be de novo, following a prior hematologic disorder including myelodysplastic syndrome or Philadelphia chromosome-negative myeloproliferative neoplasm, and/or therapy-related * Patients must have relapsed/refractory AML, with any prior therapies and any number of prior therapies, and have no further standard therapies available. * Any prior therapy must have been completed ≥2 weeks prior to Day 1 of treatment on study, and all treatment-related adverse events (except alopecia) should have recovered to \<Grade 1. * Hematologic abnormalities that are thought to be primarily related to leukemia are not considered to be toxicities and do not need to resolve to \<Grade 1. * Myeloid growth factors must have been stopped ≥1 week (filgrastim) or ≥2 weeks (pegfilgrastim) before starting study treatment. * Prior autologous hematopoietic stem cell transplantation is allowed. * Prior allogeneic hematopoietic stem cell transplantation is also allowed, if patients are ≥60 days from stem cell infusion, have no evidence of graft-versus…